"10.1371_journal.pone.0120095","plos one","2015-03-23T00:00:00Z","Evelyne Isra√´l-Assayag; Marie-Jos√©e Beaulieu; Yvon Cormier","Institut universitaire de cardiologie et de pneumologie de Qu√©bec (IUCPQ), Qu√©bec, Qu√©bec, Canada; Asmacure Lt√©e, Qu√©bec, Qu√©bec, Canada","Conceived and designed the experiments: EIA MJB YC. Performed the experiments: MJB. Analyzed the data: EIA MJB YC. Wrote the paper: EIA YC MJB.","This study was funded by Asmacure Lt√©e, EIA and YC are shareholders and part-time employees of Asmacure Lt√©e; this does not alter their adherence to all the PLOS ONE policies on sharing data and materials. Patent related to material pertinent to this article: EIA and YC are inventors and may benefit from the following patents belonging to Universit√© Laval, Quebec City, QC. Canada: Nicotinic receptor agonists for the treatment of inflammatory diseases # US8377936 B2; US 20110301152 A1; US8551983 B2; US 8557804 B2. This does not alter their adherence to all the PLOS ONE policies on sharing data and materials. Patents, all related to the cited US patents, were granted in other countries (Australia, Canada, China, Europe, Israel, Japan, Mexico, New Zealand, Russia and South Korea). ‚ÄúCombination therapy and methods for the treatment of respiratory diseases‚Äù, International publication number: WO 2014071512. There are no further patents, products in development or marketed products to declare.","2015","03","Evelyne Isra√´l-Assayag","EI√A",3,TRUE,3,1,3,3,TRUE,TRUE,FALSE,0,NA,FALSE
